A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00077623
First received: February 10, 2004
Last updated: April 26, 2016
Last verified: April 2016
  Purpose
This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.

Condition Intervention Phase
Anemia
Drug: epoetin alfa or beta
Drug: methoxy polyethylene glycol-epoetin beta (Mircera)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods [ Time Frame: Baseline (Week -4 to Week -1) and Evaluation period (Week 29 to Week 36) ] [ Designated as safety issue: No ]
    A time adjusted mean change in hemoglobin (Hb) concentration was calculated using an area under the curve (AUC) approach, for both periods separately. Change in Hb concentration between the baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb value from the average evaluation period Hb value. All blood samples for Hb measurements were taken prior to study drug administration. Analysis used last observation carried forward (LOCF) for missing Hb values to correct for the impact of early dropouts. The baseline period is defined as Week -4 to Week -1. The evaluation period is defined as Week 29 to Week 36.


Secondary Outcome Measures:
  • Number of Participants Maintaining Average Hb Concentration During the Evaluation Period Within +-1 g/dL of Their Average Baseline Hb Concentration [ Time Frame: Evaluation period (Week 29 to Week 36) ] [ Designated as safety issue: No ]
    All mean Hb values recorded during the evaluation period were calculated and subtracted from the mean baseline Hb value for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given. The evaluation period is defined as Week 29 to Week 36.

  • Number of Participants With Red Blood Cell Transfusions [ Time Frame: Up to Week 36 ] [ Designated as safety issue: No ]
    The number of participants who received RBC transfusions were reported.

  • Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Deaths [ Time Frame: Up to week 52 ] [ Designated as safety issue: No ]
    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

  • Number of Participants With Marked Laboratory Abnormalities [ Time Frame: Up to week 52 ] [ Designated as safety issue: No ]
    A marked abnormality range was defined as above and/or below a value which was considered to be potentially clinically relevant. Marked laboratory abnormalities were analyzed according to the Roche specified limits for the reference range of the following laboratory parameters: White blood cells (WBC) (3.0- 18.0 10^9/L), platelets (100 - 550 10^9/L), alanine aminotransferase (ALAT) (0 - 110 units per liter [U/L]), alkaline phosphatase (ALP [0 - 220 U/L]), aspartate aminotransferase (ASAT) (0 - 80 U/L), albumin >= 30 g/L, phosphate (0.75 - 1.60 millimoles per liter [mmol/L]), potassium (2.9 - 5.8 mmol/L), glucose (2.80 - 11.10 mmol/L).

  • Change From Baseline in Systolic and Diastolic Blood Pressure - at Weeks 36 and 52 in Hemodialysis Participants [ Time Frame: From Baseline (Week -4 to Week -1) to Week 36 and Week 52 ] [ Designated as safety issue: No ]
    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in haemodialysis participants.

  • Change From Baseline in Pulse Rate at Weeks 36 and 52 in Hemodialysis Participants [ Time Frame: From Baseline (Week -4 to Week -1) to Week 36 and Week 52 ] [ Designated as safety issue: No ]
    Pulse rate in beats per minute (BpM) was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in haemodialysis participants.

  • Change From Baseline in Systolic and Diastolic Blood Pressure at Weeks 36 and 52 in Peritoneal Dialysis Participants [ Time Frame: From Baseline (Week -4 to Week -1) to Week 36 and Week 52 ] [ Designated as safety issue: No ]
    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in peritoneal dialysis participants.

  • Change From Baseline in Pulse Rate - Peritoneal Dialysis Participants [ Time Frame: From Baseline (Week -4 to Week -1) to Week 36 and Week 52 ] [ Designated as safety issue: No ]
    Pulse rate in BpM was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in peritoneal dialysis participants.


Enrollment: 572
Study Start Date: March 2004
Study Completion Date: September 2005
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RO0503821 (1x/2 Weeks)
Eligible participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the week preceding the switch to the study drug.
Drug: methoxy polyethylene glycol-epoetin beta (Mircera)
60, 100 or 180 micrograms sc (starting dose) every 2 weeks
Experimental: RO0503821 (1x/4 Weeks)
Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of<8000, 8000-16000, or >16000 IU/week administered during the week preceding the switch to the study drug.
Drug: methoxy polyethylene glycol-epoetin beta (Mircera)
60, 100 or 180 micrograms sc (starting dose) every 4 weeks
Active Comparator: Epoetin Reference
Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .
Drug: epoetin alfa or beta
iv 3 times weekly, as prescribed

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients >=18 years of age;
  • chronic renal anemia;
  • on dialysis therapy for at least 12 weeks before screening;
  • receiving sc epoetin for at least 8 weeks before screening.

Exclusion Criteria:

  • women who are pregnant, breastfeeding or using unreliable birth control methods;
  • administration of another investigational drug within 4 weeks before screening, or during the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077623

  Hide Study Locations
Locations
United States, Arkansas
Hot Springs, Arkansas, United States, 71901
United States, California
Los Angeles, California, United States, 90033
Riverside, California, United States, 92501
Sacramento, California, United States, 95816-5119
San Jose, California, United States, 95116-1906
United States, Massachusetts
Boston, Massachusetts, United States, 02130
Springfield, Massachusetts, United States, 01107
United States, Michigan
Detroit, Michigan, United States, 48202-2689
United States, Minnesota
Brooklyn Center, Minnesota, United States, 55430
United States, North Carolina
Raleigh, North Carolina, United States, 27609
Winston-salem, North Carolina, United States, 27157-1023
United States, Ohio
Toledo, Ohio, United States, 43606
United States, Oregon
Portland, Oregon, United States, 97210
United States, Texas
Dallas, Texas, United States, 75216
Houston, Texas, United States, 77030
San Antonio, Texas, United States, 78229
United States, West Virginia
Morgantown, West Virginia, United States, 26506
Belgium
Bruxelles, Belgium, 1090
Edegem, Belgium, 2650
Gent, Belgium, 9000
Hasselt, Belgium, 3500
Brazil
Curitiba, Brazil, 81050-090
Sao Paulo, Brazil, 03065-000
Sao Paulo, Brazil, 04039-000
Czech Republic
Brno, Czech Republic, 656 91
Ostrava, Czech Republic, 708 52
Plzen, Czech Republic, 304 60
Denmark
Odense, Denmark, 5000
Finland
HUS, Finland, 00029
Tampere, Finland, 33521
Turku, Finland, 20521
France
Bayonne, France, 64115
Boulogne, France, 62321
Cabestany, France, 66330
Caen, France, 14033
Limoges, France, 87042
Nimes, France, 30029
Pantin, France, 93500
Poitiers, France, 86021
Saint-germain-en-laye, France, 78100
St Priest En Jarez, France, 42055
Thionville, France, 57126
Tours, France, 37044
Germany
Bad Hersfeld, Germany, 36251
Berlin, Germany, 12045
Kaiserslautern, Germany, 67655
Hungary
Budapest, Hungary, 1076
Budapest, Hungary, 1134
Debrecen, Hungary, 4032
Miskolc, Hungary, 3526
Pecs, Hungary, 7624
Italy
Cremona, Italy, 26100
Lecco, Italy, 23900
Mestre, Italy, 30174
Modena, Italy, 41100
Prato, Italy, 50047
Venezia, Italy, 30122
Mexico
Cuernavaca, Mexico, 62448
Mexico City, Mexico, 14000
New Zealand
Christchurch, New Zealand
Wellington, New Zealand
Panama
Panama City, Panama, 0
Poland
Gdansk, Poland, 80-211
Kielce, Poland, 25-736
Krakow, Poland, 31-501
Wroclaw, Poland, 50-417
Puerto Rico
Ponce, Puerto Rico, 00732
South Africa
Durban, South Africa
Spain
Alcorcon, Spain, 28922
Barcelona, Spain, 08035
Madrid, Spain, 28006
Madrid, Spain, 28046
Palma de Mallorca, Spain, 07198
Pamplona, Spain, 31008
Santiago de Compostela, Spain, 15706
Sweden
Huddinge, Sweden, 14186
Karlstad, Sweden, 65185
Taiwan
Taichung, Taiwan, 407
Taipei, Taiwan, 100
Thailand
Bangkok, Thailand, 10310
Bangkok, Thailand, 10400
Phitsanulok, Thailand, 65000
United Kingdom
Belfast, United Kingdom, BT9 7LJ
Cambridge, United Kingdom, CB2 2QQ
Dundee, United Kingdom, DD1 9SY
Exeter, United Kingdom, EX2 5DW
Leicester, United Kingdom, LE5 4PW
London, United Kingdom, SE1 9RT
London, United Kingdom, SE22 8PT
London, United Kingdom, SW17 0RE
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00077623     History of Changes
Other Study ID Numbers: BA16740 
Study First Received: February 10, 2004
Results First Received: March 24, 2016
Last Updated: April 26, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Anemia
Hematologic Diseases
Epoetin Alfa
Hematinics

ClinicalTrials.gov processed this record on July 27, 2016